The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant

References

• Poland GA, Murray D, Bonilla-Guerrero R. New vaccine development. BMJ324(7349), 1315–1319 (2002).
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Miller HI, Falkow S. Medicine. The intangible value of vaccination. Science297(5583), 937–939 (2002).
   PubMed Web of Science ®Google Scholar
• Bonanni P. Demographic impact of vaccination: a review. Vaccine17(Suppl. 3), S120–S125 (1999).
   PubMed Web of Science ®Google Scholar
• Samant Y, Lanjewar H, Parker D, Block L, Tomar GS, Stein B. Evaluation of the cold-chain for oral polio vaccine in a rural district of India. Pub. Health Rep.122(1), 112–121 (2007).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – ‘The long and winding road’. Drug Discov. Today.14(11–12), 541–551 (2009).
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol.15(6), 677–682 (2003).
   PubMed Web of Science ®Google Scholar
• Dorner F, Barrett PN. Vaccine technology: looking to the future. Ann. Med.31(1), 51–60 (1999).
   PubMed Web of Science ®Google Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci.65(20), 3231–3240 (2008).
   PubMed Web of Science ®Google Scholar
• Mullen GED, Aebig JA, Dobrescu G et al. Enhanced antibody production in mice to the malaria antigen AMA 1 by CPG 7909 requires physical association of CpG and antigen. Vaccine25(29), 5343–5347 (2007).
   PubMed Web of Science ®Google Scholar
• Hogenesch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine20, S34–S39 (2002).
   PubMed Web of Science ®Google Scholar
• Langer R. Polymeric delivery systems for controlled drug release. Chem. Eng. Communicat.6(1–3), 1–48 (1980).
   Web of Science ®Google Scholar
• Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm.364(2), 298–327 (2008).
   PubMed Web of Science ®Google Scholar
• Saez V, Hernandez JR, Peniche C. Microspheres as delivery systems for the controlled release of peptides and proteins. Biotecnol. Aplicada24, 108–116 (2007).
   Google Scholar
• Brown LR. Commercial challenges of protein drug delivery. Exp. Opin. Drug Deliv.2(1), 29–42 (2005).
   PubMedGoogle Scholar
• Bramwell VW, Eyles JE, Alpar HO. Particulate delivery systems for biodefense subunit vaccines. Adv. Drug Deliv. Rev.57(9), 1247–1265 (2005).
   PubMed Web of Science ®Google Scholar
• Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm.50(1), 129–146 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Singh M, O’Hagan DT. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev.32(3), 225–246 (1998).
   PubMed Web of Science ®Google Scholar
• Johansen P, Corradin G, Merkle HP, Gander B. Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern. J. Control. Release56(1–3), 209–217 (1998).
   PubMed Web of Science ®Google Scholar
• Johansen P, Estevez F, Zurbriggen R et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine19(9–10), 1047–1054 (2000).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, Wang H et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun.65(5), 1716–1721 (1997).
   PubMed Web of Science ®Google Scholar
• Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J. Pharm. Sci.92(5), 957–966 (2003).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, Mcgee JP et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine15(5), 475–481 (1997).
   PubMed Web of Science ®Google Scholar
• Shi L, Caulfield MJ, Chern RT, Wilson RR, Sanyal G, Volkin DB. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci.91(4), 1019–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Feng L, Qi XR, Zhou XJ et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release112(1), 35–42 (2006).
   PubMed Web of Science ®Google Scholar
• Johansen P, Tamber H, Merkle HP, Gander B. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. Eur. J. Pharm. Biopharm.47(3), 193–201 (1999).
   PubMed Web of Science ®Google Scholar
• Singh M, Singh A, Talwar GP. Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules. Pharm. Res.8(7), 958–961 (1991).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, Wang H et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine16(4), 346–352 (1998).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Reid RH, Boedeker EC et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine12(14), 1270–1274 (1994).
   PubMed Web of Science ®Google Scholar
• Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J. Microencapsulat.15(6), 699–713 (1998).
   PubMed Web of Science ®Google Scholar
• Xie JW, Wang CH. Encapsulation of proteins in biodegradable polymeric microparticles using electrospray in the Taylor Cone-Jet mode. Biotechnol. Bioeng.97(5), 1278–1290 (2007).
   PubMed Web of Science ®Google Scholar
• Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J. Pharmaceut. Sci.97(7), 2395–2404 (2008).
   PubMed Web of Science ®Google Scholar
• Park TG, Mok H, Park JW. Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency. Pharmaceut. Res.24(12), 2263–2269 (2007).
   PubMed Web of Science ®Google Scholar
• Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL. Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. Intl J. Pharmaceut.169(1), 45–54 (1998).
   Web of Science ®Google Scholar
• Perez C, Griebenow K. Improved activity and stability of lysozyme at the water/CH2Cl2 interface: enzyme unfolding and aggregation and its prevention by polyols. J. Pharm. Pharmacol.53(9), 1217–1226 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu GZ, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat. Biotechnol.18(1), 52–57 (2000).
   PubMed Web of Science ®Google Scholar
• Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J. Pharm. Pharmacol.56(10), 1243–1250 (2004).
   PubMed Web of Science ®Google Scholar
• Ding AG, Schwendeman SP. Acidic Microclimate pH Distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharmaceut. Res.25(9), 2041–2052 (2008).
   PubMed Web of Science ®Google Scholar
• Langer R. Drug delivery and targeting. Nature392(6679), 5–10 (1998).
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines9(9), 1095–1107 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao X, Jain S, Benjamin Larman H, Gonzalez S, Irvine DJ. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials26(24), 5048–5063 (2005).
   PubMed Web of Science ®Google Scholar
• Singh M, Singh O, Talwar GP. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharm. Res.12(11), 1796–1800 (1995).
   PubMed Web of Science ®Google Scholar
• Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials21(23), 2475–2490 (2000).
   PubMed Web of Science ®Google Scholar
• Van De Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res.17(10), 1159–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Zhu G, Schwendeman SP. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives. Pharm. Res.17(3), 351–357 (2000).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Lin W, Jenkins P et al. Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine18(3–4), 238–250 (1999).
   PubMed Web of Science ®Google Scholar
• Jiang W, Schwendeman SP. Stabilization of a model formalinized protein antigen encapsulated in poly(lactide-co-glycolide)-based microspheres. J. Pharm. Sci.90(10), 1558–1569 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang W, Schwendeman SP. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Mol. Pharm.5(5), 808–817 (2008).
   PubMed Web of Science ®Google Scholar
• Singh M, Chesko J, Kazzaz J et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm. Res.21(12), 2148–2152 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Chesko J et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci.93(2), 273–282 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Ugozzoli M, Malyala P, Chesko J, O’Hagan DT. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv.3(1), 115–120 (2006).
   PubMedGoogle Scholar
• Chesko J, Kazzaz J, Ugozzoli M, O’Hagan DT, Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. J. Pharm. Sci.94(11), 2510–2519 (2005).
   PubMed Web of Science ®Google Scholar
• Jain S, Malyala P, Pallaoro M et al. A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery. J. Pharm. Sci.100(2), 646–654 (2011).
   PubMed Web of Science ®Google Scholar
• Lamalle-Bernard D, Munier S, Compagnon C et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J. Control. Release115(1), 57–67 (2006).
   PubMed Web of Science ®Google Scholar
• Luten J, Van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release126(2), 97–110 (2008).
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, Mackichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene. Ther.7(24), 2105–2112 (2000).
   PubMed Web of Science ®Google Scholar
• Mollenkopf HJ, Dietrich G, Fensterle J et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine22(21–22), 2690–2695 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Dong C et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine23(5), 672–680 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA vaccines. Immunol. Rev.199, 191–200 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA97(2), 811–816 (2000).
   PubMed Web of Science ®Google Scholar
• Singh M, Vajdy M, Gardner J, Briones M, O’Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine20(3–4), 594–602 (2001).
   PubMed Web of Science ®Google Scholar
• Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(D,L-lactide-co-glycolide): stability issues and release characteristics. J. Control. Release61(3), 361–374 (1999).
   PubMed Web of Science ®Google Scholar
• Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharmaceut. Sci.88(1), 126–130 (1999).
   PubMed Web of Science ®Google Scholar
• Briones M, Singh M, Ugozzoli M et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharmaceut. Res.18(5), 709–712 (2001).
   PubMed Web of Science ®Google Scholar
• Spearman P, Lally MA, Elizaga M et al. A trimeric, V2-Deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Discov.203(8), 1165–1173 (2011).
   PubMed Web of Science ®Google Scholar
• Hayakawa I, Kajihara J, Morikawa K, Oda M, Fujio Y. Denaturation of bovine serum-albumin (Bsa) and ovalbumin by high-pressure, heat and chemicals. J. Food Sci.57(2), 288–292 (1992).
   Web of Science ®Google Scholar
• Stern AM, Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Affairs24(3), 611–621 (2005).
   PubMed Web of Science ®Google Scholar
• Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers. Biomaterials17(2), 93–102 (1996).
   PubMed Web of Science ®Google Scholar
• Carrascosa C, Espejo L, Torrado S, Torrado JJ. Effect of γ-sterilization process on PLGA microspheres loaded with insulin-like growth factor-I (IGF-I). J. Biomater. Applicat.18(2), 95–108 (2003).
   PubMed Web of Science ®Google Scholar
• Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine12(4), 299–306 (1994).
   PubMed Web of Science ®Google Scholar
• Guillon C, Mayol K, Terrat C et al. Formulation of HIV-1 tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine25(43), 7491–7501 (2007).
   PubMed Web of Science ®Google Scholar
• Quintilio W, Takata CS, Sant’anna OA, Da Costa MH, Raw I. Evaluation of a diphtheria and tetanus PLGA microencapsulated vaccine formulation without stabilizers. Curr. Drug Deliv.6(3), 297–304 (2009).
   PubMedGoogle Scholar
• O’Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Therapeut.82(6), 740–744 (2007).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines6(5), 699–710 (2007).
   PubMed Web of Science ®Google Scholar
• Paschke R, Pollok M, Geiger H et al. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional sub-unit vaccine in renal transplant recipients. J. Prevent. Med. Hygiene44, 79–84 (2003).
   Google Scholar
• Esposito S, Pugni L, Daleno C et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics127(5), E1161–E1168 (2011).
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O’Hagan DT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release110(3), 566–573 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, Barzee S, Snarsky V et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma. PLoS One4(10), e7334 (2009).
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine22(19), 2406–2412 (2004).
   PubMed Web of Science ®Google Scholar
• Hamdy S, Molavi O, Ma Z et al. Co-delivery of cancer-associated antigen and toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine26(39), 5046–5057 (2008).
   PubMed Web of Science ®Google Scholar
• Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv.1(4), 405–412 (2004).
   PubMedGoogle Scholar
• Malyala P, O’hagan DT, Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv. Drug Deliv. Rev.61(3), 218–225 (2009).
   PubMed Web of Science ®Google Scholar
• Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, De Vries IJ, Figdor CG. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J. Immunol.184(8), 4276–4283 (2010).
   PubMed Web of Science ®Google Scholar
• Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol.37(8), 2063–2074 (2007).
   PubMed Web of Science ®Google Scholar
• Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature470(7335), 543–547 (2011).
   PubMed Web of Science ®Google Scholar
• Westwood A, Elvin SJ, Healey GD, Williamson ED, Eyles JE. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Vaccine24(11), 1736–1743 (2006).
   PubMed Web of Science ®Google Scholar
• Wischke C, Zimmermann J, Wessinger B et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm.365(1–2), 61–68 (2009).
   PubMed Web of Science ®Google Scholar
• Lee YR, Lee YH, Im SA et al. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. Arch. Pharm. Res.33(11), 1859–1866 (2010).
   PubMed Web of Science ®Google Scholar
• Lima KM, Santos SA, Lima VM, Coelho-Castelo AA, Rodrigues JM Jr, Silva CL. Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther.10(8), 678–685 (2003).
   PubMed Web of Science ®Google Scholar
• Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol.27(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Mutwiri G, Gerdts V, Van Drunen Littel-Van Den Hurk SV et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines10(1), 95–107 (2011).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• Dunne A, Marshall NA, Mills KH. TLR based therapeutics. Curr. Opin. Pharmacol.11(4), 404–411 (2011).
   PubMed Web of Science ®Google Scholar
• Weissburg RP, Berman PW, Cleland JL et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm. Res.12(10), 1439–1446 (1995).
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J. Immunother.30(4), 378–395 (2007).
   PubMed Web of Science ®Google Scholar
• Groettrup M, Schlosser E, Mueller M et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine26(13), 1626–1637 (2008).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines2(2), 269–283 (2003).
   PubMedGoogle Scholar
• Didierlaurent AM, Morel S, Lockman L et al. AS04, an Aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol.183(10), 6186–6197 (2009).
   PubMed Web of Science ®Google Scholar
• Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines6(5), 797–808 (2007).
   PubMed Web of Science ®Google Scholar
• Wesselinova D. Current major cancer targets for nanoparticle systems. Curr. Cancer Drug Targets11(2), 164–183 (2011).
   PubMed Web of Science ®Google Scholar
• Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol.9(1), 10–16 (1997).
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon Gl. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceut. Res.14(11), 1568–1573 (1997).
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm.298(2), 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Katare YK, Muthukumaran T, Panda AK. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int. J. Pharmaceut.301(1–2), 149–160 (2005).
   PubMed Web of Science ®Google Scholar
• Ohagan DT, Jeffery H, Davis SS. Long-term antibody-responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine11(9), 965–969 (1993).
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods40(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Manolova V, Flace A, Bauer M, Schwarz K, Saudan P. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol.38(5), 1404–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol.10(11), 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• Samuelsen M, Nygaard UC, Lovik M. Particle size determines activation of the innate immune system in the lung. Scand. J. Immunol.69(5), 421–428 (2009).
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol.173(5), 3148–3154 (2004).
   PubMed Web of Science ®Google Scholar
• Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine21(1–2), 67–77 (2002).
   PubMed Web of Science ®Google Scholar
• Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials28(35), 5344–5357 (2007).
   PubMed Web of Science ®Google Scholar
• Wendorf J, Chesko J, Kazzaz J et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vacc.4(1), 44–49 (2008).
   PubMed Web of Science ®Google Scholar
• Mohanan D, Slutter B, Henriksen-Lacey M et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release147(3), 342–349.
   Google Scholar
• Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo.J. Biomed. Mater. Res.60(3), 480–486 (2002).
   PubMed Web of Science ®Google Scholar
• Reddy ST, Van Der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol.25(10), 1159–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Pollock KM, Yoshida M, Lahann J. Towards designer microparticles: simultaneous control of anisotropy, shape, and size. Small6(3), 404–411 (2010).
   PubMed Web of Science ®Google Scholar
• Glangchai LC, Caldorera-Moore M, Shi L, Roy K. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J. Control. Release125(3), 263–272 (2008).
   PubMed Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA105(33), 11613–11618 (2008).
   PubMed Web of Science ®Google Scholar
• Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release121(1–2), 3–9 (2007).
   PubMed Web of Science ®Google Scholar
• Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton)10(3), 317–320 (2005).
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang YC, Wu YT, Huang HY. Surfactant-free formulation of poly(lactic/glycolic) acid nanoparticles encapsulating functional polypeptide: a technical note. Aaps. Pharmscitech10(4), 1263–1267 (2009).
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release67(2–3), 347–356 (2000).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Roberts MJ, Mcgee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine9(10), 768–771 (1991).
   PubMed Web of Science ®Google Scholar
• Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Exp. Rev. Mol. Med.9(3), 1–17 (2007).
   PubMedGoogle Scholar
• Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine28(31), 4880–4894 (2010).
   PubMed Web of Science ®Google Scholar
• Allison AC, Gregoria G. Liposomes as immunological adjuvants. Nature252(5480), 252–252 (1974).
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane-proteins from enveloped viruses. Nature308(5958), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology259(2), 256–261 (1999).
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX (TM). Vaccine27(33), 4388–4401 (2009).
   PubMed Web of Science ®Google Scholar
• Okada H, Heya T, Ogawa Y, Toguchi H, Shimamoto T. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate. Pharmaceut. Res.8(5), 584–587 (1991).
   PubMed Web of Science ®Google Scholar
• Dean RL. The preclinical development of medisorb naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front. Biosci.10, 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Quarmby V. Immunogenicity in biotherapeutic development: utility of preclinical data. Presented at: Workshop on Protein Aggregation and Immunogenicity/ Breckenridge, CO, USA, 20 July 2010.
   Google Scholar
• Chesko J, Kazzaz J, Ugozzoli M et al. Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS. J. Pharm. Sci.97(4), 1443–1453 (2008).
   PubMed Web of Science ®Google Scholar